Edgewise Therapeutics, Inc. (EWTX)
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$167.8M
- Total assets
- $552.6M
- Market cap
- $3.8B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $191.4M
- Operating income
- -$191.4M
- Income tax
- $4.0K
- Net income
- -$167.8M
- EPS (basic)
- $-1.63
- EPS (diluted)
- $-1.63
Balance sheet
- Total assets
- $552.6M
- Current assets
- $543.4M
- Total liabilities
- $30.3M
- Current liabilities
- $27.4M
- Shareholders’ equity
- $522.3M
Cash flow
- Operating cash flow
- -$143.8M
- Investing cash flow
- -$32.8M
- Financing cash flow
- $196.1M
- Net cash flow
- $19.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $3.8B
- EPS (diluted)
- $-1.63
- Shares outstanding
- 93.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 26, 2021
Edgewise Therapeutics, Inc. (EWTX) Stock Price
- Reported a net loss of $167.8M.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Edgewise Therapeutics, Inc..
Write a review
News about Edgewise Therapeutics, Inc.
News & sentiment via Polygon.io
Edgewise Therapeutics, Inc.: frequently asked questions
Is Edgewise Therapeutics, Inc. an American company?
Edgewise Therapeutics, Inc. is a US-based company headquartered in Boulder, Colorado, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Edgewise Therapeutics, Inc. headquartered?
Edgewise Therapeutics, Inc. is headquartered in Boulder, Colorado, United States.
Is Edgewise Therapeutics, Inc. publicly traded?
Yes — Edgewise Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol EWTX on the NASDAQ.
What does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
